Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do surgery quality rules save lives in ovarian cancer?

NCT ID NCT07567573

Knowledge-focused Sponsor: European Society of Gynaecological Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed over 11,000 patients with advanced ovarian cancer to see if hospitals that follow ten specific quality standards for surgery have better outcomes. The research looked at how long patients lived without their cancer getting worse and overall survival. The goal is to find out which standards matter most and help improve care for future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

11,383 people

The number who actually took part.

Started

Apr 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are individuals treated for advanced or recurrent ovarian cancer at ESGO-accredited centers across multiple countries. These centers include institutions with standard accreditation and centers of excellence, representing a diverse geographical and clinical practice setting. The study population reflects patients managed within routine clinical care during the period 2020-2022.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient presented at an ESGO-accredited centre between January 1, 2020 and December 31, 2022 * Newly diagnosed FIGO stage III or IV ovarian cancer (surgical and non-surgical cases), OR * Relapsed ovarian cancer undergoing secondary or tertiary cytoreductive surgery (surgical cases only) * All consecutive incoming ovarian cancer patients within the specified time frame were documented to avoid selection bias Exclusion Criteria: * Age \<18 years at first diagnosis * Relapsed ovarian cancer undergoing surgery for palliative intent (no cytoreductive surgery) * Early-stage ovarian cancer at first diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced-stage ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual ovarian cancer Postoperative Complications Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced-stage ovarian cancer D010051 Figo stages III and IV Ovarian cancer Quality indicators

Contacts and locations

Locations

  • European Society of Gynaecological Oncology Aisbl

    Brussels, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.